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 Two adult female patients with established Graves' dis-
ease were treated with propylthiouracil (PTU). One patient 
developed agranulocytosis, high fever of unknown origin 
and bilateral episcleritis. Another patient reported repeated 
attacks of common cold-like symptoms, polyarthralgia and 
skin purpura. There was no hematuria or proteinuria. 
Administration of PTU was withdrawn following identifica-
tion of high myeloperoxidase-antineutrophil cytoplasmic an-
tibody (MPO-ANCA) titer in the serum. Without steroids or 
immunosuppressive therapy, symptoms improved gradually 
in association with a fall in serum MPO-ANCA titer. We 
speculated that the symptoms of our two cases were due to 
MPO-ANCA associated vasculitis. MPO-ANCA positive vasculitis 
and glomerulonephritis are rare complications of PTU ther-
apy, however, when these occur, the condition may become 
serious. Patients with Graves' disease treated with PTU 
should be carefully observed during therapy.
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Introduction
 Graves' disease is a common autoimmune disorder 
and can usually be controlled by antithyroid drugs, 
such as methimazol N MI) and propylthiouracil (PTU). 
However, these drugs have several adverse effects such 
as skin eruption, liver dysfunction, agranulocytosis. 
Antineutrophil cytoplasmic antibody (ANCA) is an 
important serological marker for systemic vasculitic 
disorders. Recently, few studies reported that patients
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with Graves' disease treated by PTU might develop 
ANCA-positive vasculitis or crescentic glomerulonephritis 
(1-5) . We report two patients with Graves' disease who 
had high serum titers of ANCA and developed vasculitis-
like disorders during PTU therapy.
Case reports
Case 1 
 Diagnosis of Graves' disease was established in a 46-
year-old woman at the age of 22 years following presen-
tation with tremors, weight loss and palpitation. She was 
treated with MMI but it was withdrawn two years later 
because of normalization of thyroid function after deliv-
ery. At the age of 26, she became pregnant again and 
developed a relapse of hyperthyroidism during the 
first trimester. Accordingly, she was treated with 300 
mg of PTU. Treatment with PTU was continued for 10 
years, followed by a remission for 9 years. At that 
stage, she noticed general malaise, weight loss, tremor 
and pretibial edema, which were later confirmed to be due 
to a relapse of hyperthyroidism. She was treated again 
with 150 mg PTU, but two weeks later she developed high 
fever, which continued for 11 days in spite of continued 
medication with antibiotics and anti-inflammatory drugs. 
At that stage, severe leukocytopenia (700 cells/ml) was 
noted, and accordingly she was referred and admitted to 
our hospital. 
 On clinical examination, heart rate was 118 beats/min 
and blood pressure 120/70 mmHg. The thyroid gland was 
diffusely enlarged on both sides and soft on palpation. 
Chest auscultation identified a systolic heart murmur. 
Finger tremor and pretibial edema were noted. Laboratory 
data on admission showed severe leukocytopenia (800/ml) 
and moderate anemia (Table 1). Examination of a bone 
marrow smear showed hypercellular marrow, predomi-
nantly containing plasma cells and cells of erythrocyte
Table 1. Laboratory data on admission (Case 1)
WBC (3600-8500) 800//11 IgG (972-2010) 23711U/ml urine 
RBC (3.9-5.0x104) 426x104//11 IgA (90-445) 1851U/m1 blood negative 
 Hb (11.0-14.5) 10.8g/dl IgM (67-359) 3181U/ml protein negative 
 Pit (15.0-38.0) 19.8x104/ u I CH50 (20-60) 37.7)u g/ml sugar negative 
T.P (6.2-8.0) 7.0g/d1 ANA (negative) negative cast negative 
Alb (3.8-4.9) 3.1g/d1 anti-dsDNAAb (negative) 24x 
BUN (8.0-12.0) 12mg/d1 FT3 (2.7-4.5) 3.7pg/ml 
 Cr (0.3-1.0) 0.7mg/dl FT4 (1.0-1.8) 1.7ng/ml 
CRP (<0.17) 13.6mg/dl TSH (0.3-3.2) <0.01 /1 U/ml 
PT (82-127) 49% TRAb (<10) 0.10% 
APTT (25.2-34.4) 39.2s MPO-ANCA (<10) 143EU 
Fbg (168-329) 774mg/dl C-ANCA (<10) 13EU
TRAb; TSH-receptor antibody, MPO-ANCA; myeroperoxidase 
C-ANCA; anti-neutrophilic cytoplasmic antibody,
series. Serum thyroid hormone concentrations were normal 
and both anti-thyroglobulin and microsome antibodies were 
negative, but CRP was high. Urinalysis showed no protein, 
cells, or casts. The chest radiograph was negative but 
marked splenomegaly was noted on abdominal 
ultrasonography. Serum titer of myeloperoxidase-
ANCA (MPO-ANCA) was high (143 EU) by ELISA 
(cut off value< 10), and cytoplasmic-ANCA (C-ANCA) 
was 13 EU (cut off value< 10) (Fig. 1).
Fig. 1. Clinical course in Case 1.
 PTU was withdrawn on admission because of 
granulocytopenia, and she was treated with antibiotics 
and G-CSF. This resulted in a rapid increase in leuko-
cyte count, but the patient continued to have high 
fever. No infectious focus was detected in spite of sev-
eral examinations. High fever, however disappeared six
weeks after withdrawal of PTU, associated with a fall in 
MPO-ANCA titer without steroids or immunosuppressive 
therapy. The patient was also found to have bilateral 
episcleritis on admission. Episcleritis is an important sign 
from vasculitis. For this reason, it was assumed that 
the high fever and bilateral episcleritis were due to 
MPO-ANCA associated vasculitis. Her symptoms and 
signs were spontaneously disappeared after withdrawal 
of PTU therapy. 131I therapy was administered for 
Graves' disease and MPO-ANCIA fell to 41 EU after 3 
years.
Case 2 
 Graves' disease was diagnosed in a 38-year-old 
woman after she consulted her family physician for 
palpitation, excessive sweating and diarrhea. At that 
time, thymoma was noticed on chest CT examination. 
The patient was treated with methimazol (MMI) first. 
As skin eruption appeared soon after therapy, and ac-
cordingly MMI was replaced with PTU. The symptoms 
improved with the return of thyroid function to the 
normal range. However, the patient complained of fre-
quent attacks of sore throat, cough and hemosputum 8 
months later in spite of euthyroid state. Lung fields 
were clear on chest radiograph and the patient was ad-
vised to continue with PTU medication. Fifteen months 
later, heart murmur and cardiomegaly were noticed, and a 
diagnosis of moderate aortic valve regurgitation (AR) 
and mild stenosis (AS) was established based on 
cardioechography. Operation for AR was offered but 
the patient refused surgery, and, accordingly, ASR was 
followed up in our outpatient clinic. On the other 
hand, chest CT showed a mixed density tissue but not 
mass-like shadow in the anterior mediastinum, which 
was suspected to be thymic hyperplasia. After 2 years 
of PTU treatment, the patient developed arthralgia, 
myalgia and skin purpura. Worsening of clinical condi-
tion and remission of symptoms occurred persistently 
throughout a 6-month period. Thyroid hormone levels 
were almost within the normal range under PTU (100-200 
mg/day) therapy and anti-thyroglobulin and microsome 
antibodies were positive (X 1,600 and X 102,400, respec-
tively). Leukocyte count, CRP and CH5o were normal, and 
rheumatoid factor and anti-ds-DNA antibody were nega-
tive. Urinalysis showed no protein, occult blood, cells, or 
casts. However, platelet count was slightly decreased (13-
14 X 104//1         1), and MPO-ANCA titer was markedly high 
(587 EU), C-ANCA was also above the normal range (20 
EU) (Fig. 2). 
 Because of the high titer of MPO-ANCA, we sus-
pected that the multitude of symptoms (common cold, 
arthralgia, myalgia and purpura) were due to MPO-
ANCA associated vasculitis. Accordingly, PTU therapy 
was terminated and 131I therapy was initiated for 
Graves' disease. Vasculitis-like symptoms resolved and 
MPO-ANCA diminished to 254 EU two months after 
withdrawal of PTU therapy without steroids or 
immunosuppressive therapy.
Fig. 2. Clinical course in Case 2.
Table 2. Laboratory data on admission (Case 2 )
WBC (3600-8500) 7100/M I C, (42-107) 60mg/dl urine 
RBC (3.9-5.Oxl0°) 439x10'//1I C, (14-40) 14mg/dl blood negative 
Hb (11.0-14.5) 12.2g/dl RF (negative) negative protein negative 
Pit (15.0-38.0) 13.5x10'/JU I ANA (negative) negative sugar negative 
T.P (6.2-8.0) 6.3g/dl anti-dsDNAAb (negative) negative cast negative 
Alb (3.8-4.9) 4.0g/dl FT, (2.7-4.5) 2.8pg/ml 
BUN (8.0-12.0) 17mg/dl FT, (1.0-1.8) 1.Ong/ml 
Cr (0.3-1.0) 0.7mg/dl TSH (0.3-3.2) 0.82 u U/ml 
CRP (<0.17) 0.21mg/dl TSAb (<180%) 112% 
IgG (972-2010) 23711U/ml MPO-ANCA (<10) 143EU 
IgA (90-445) 1851U/ml C-ANCA (<10) 13EU 
IgM (67-359) 3181U/ml
Discussion
 ANCA was first detected in patients with necrotizing 
crescentic glomerulonephritis (NCGN). ANCA has also 
been reported in Wegener granulomatosis and micro-
scopic polyarteritis. The target antigens of the most 
common ANCA are proteinase 3 (PR3) and MPO. Anti-
PR3 is associated with Wegener's granulomatosis, while 
anti-MPO occurs predominantly in patients with NCGN. 
 Vasculitis is an uncommon complication of PTU 
treatment. Dolman et al. (1) were the first group to re-
port the concept of ANCA-associated vasculitis in-
duced by PTU. In addition, ANCA related crescentic
glomerulonephritis was reported as a severe complication 
of treatment with PTU (2, 3). Although common adverse 
effects usually arise within several weeks of initiation of 
PTU therapy, vasculitis may develop after several months 
or even years of therapy (4). Fever, arthralgia, myalgia, 
common cold-like symptoms, hematuria, proteinuria and 
skin lesions may be common findings in vasculitis. 
Episcleritis is also one of important ocular compications 
from vasculitis (5, 6). Several studies have described the 
association between PTU and ANCA-associated vasculitis. 
Vasculitis associated with PTU may affect any organ 
with skin lesions being the most common. Skin lesions 
are often of purpuric type but pain and necrotic ul-
ceration may occur. Based on the clinical presentation 
and course, our two cases are similar to those reported 
by Dolman et al. (1). 
 MPO-ANCA has been recently suggested to play a role 
in the pathogenesis of vasculitis and ANCA have been 
implicated in the development of tissue damage in 
vasculitis or glomerulonephritis (8, 9). Possible mecha-
nisms include activation of primed neutrophils to 
degranulate and to produce oxygen radicals, and inter-
ference by ANCA of MPO enzyme activity. Moreover, 
several cytokines (IL-1, 6, 8) are thought to be in-
volved in the pathogenesis of vasculitis. On the other 
hand, the mechanism of MPO-ANCA synthesis remains 
unknown. Production of MPO-ANCA is thought to 
occur through a direct effect of PTU itself or its me-
tabolites. Others have suggested that the onset of this 
complication may be part of the autoimmune process 
of Graves' disease or because anti-thyroperoxidase (TPO ) 
antibody cross-reacts with leukocyte myeloperoxidase 
(MPO) (11). Homology of MPO relative to TPO is re-
ported to be 42% (10). In our two cases, Case 1 was 
negative and Case 2 was positive for anti-microsome 
antibody. In MPO-ANCA positive patients, a positive 
anti-microsome test has been reported in 28% of such 
patients, although a lack of correlation between the 
two antibodies has also been reported (12). In this re-
gard, Vogt et al. (2) suggested that PTU changes the 
structure of epitope of MPO to a modified self-antigen, 
which is related to production of MPO-ANCA. Choi et 
al. (13) recently reported the first case of alternating 
ANCA types associated with PTU in a patient with 
preexisting C-ANCA positive Wegener' granulomatosis, 
which provided compelling evidence for the causal 
role of PTU. Appearance of ANCA in the serum has 
also been reported in patients treated with other drugs 
including hydralazine (14) and penicillamine (15) and 
minocycline (16). However, the mechanism of produc-
tion also remains unknown. In general, most patients 
with MPO-ANCA associated vasculitis improve clini-
cally as MPO-ANCA titers fall after withdrawal of
PTU provided renal involvement is limited. However, 
in some severe cases with vasculitis or nephritis, ster-
oids or immunosuppressive therapy is necessary (17). 
 Honda et al. (12) reported that the positive rate of 
MPO-ANCA among patients with Graves' disease 
treated with PTU was 19.2% and 2.0% in those 
treated with MMI. However, all MPO-ANCA positive 
patients showed no symptoms of vasculitis or nephri-
tis in their report. It is likely that interstitial 
pneumonitis, interstitial nephritis and polyarthritis re-
ported as complications of PTU are related to ANCA-
associated vasculitis. 
 In conclusion, we reported two interesting cases of 
MPO-ANCA positive vasculitis without renal injury in 
the long clinical course of Graves' disease. This compli-
cation may be facilitated by a simultaneous use of 
antithyroid drugs, but accumulation of similar cases is 
necessary to clarify the precise pathogenesis of MPO-
ANCA associated vasculitis in the course of Graves' 
disease. Symptoms and signs related to vasculitis 
should be carefully followed up in Graves' patients 
treated with PTU.
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